Print
Email
Print Edition Stories
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Ovatech Inc., a women’s health tech startup in Auburndale, has completed a Phase 2 clinical trial of its non-hormonal, intravaginal contraceptive ring, called Ovaprene.
At the end of the study, Ovatech reported its one-size-fits-all, organic silicone ring succeeded 100 percent of the time for its 85 female users in staying in place, with no motile sperm. The contraceptive is made to release spermiostatic and spermicidal agents continuously over four weeks. The company did not report any possible side effects but did note a Phase 1 study concluded that the device was “well-tolerated.”
A news release in March indicated that Ovatech expects its contraceptive ring to compete with current contraceptive devices like the diaphragm and the hormone-based vaginal ring. The company also noted it plans to begin Phase 3 trials this year.
Founded in 2009, Ovatech is led by president and CEO John Williams, a former president and CEO of several life science startups including Cappella Inc. and Physiometrix Inc., a medical devices company he led to an IPO and sold to Hospira Inc. in 2005. He notes in his own LinkedIn profile that he specializes in “starting, building and selling life science companies.” Williams is also listed as the managing director of the Yankee Equity Solutions Medical Technology Fund, with $50 million in equity.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
